Browse

Solid-organ malignancy as a risk factor for tuberculosis

Cited 48 time in Web of Science Cited 55 time in Scopus
Authors
Kim, Hye-Ryoun; Hwang, Seung Sik; Ro, Yun Kwan; Jeon, Chang Ho; Ha, Dong Yeob; Park, Sung Joon; Lee, Chang-Hoon; Lee, Sang-Min; Yoo, Chul-Gyu; Kim, Young Whan; Han, Sung Koo; Shim, Young-Soo; Yim, Jae-Joon
Issue Date
2008-04-11
Publisher
Wiley-Blackwell
Citation
Respirology. 2008; 13(3): 413-419
Keywords
AdolescentAdultAgedAged, 80 and overAntineoplastic Agents/therapeutic useBreast Neoplasms/drug therapy/*epidemiologyCase-Control StudiesCohort StudiesColonic Neoplasms/drug therapy/*epidemiologyDrug TherapyFemaleHumansImmunosuppressionLiver Neoplasms/drug therapy/*epidemiologyLung Neoplasms/drug therapy/*epidemiologyMaleMiddle AgedRegression AnalysisRetrospective StudiesRisk FactorsStomach Neoplasms/drug therapy/*epidemiologyTuberculosis, Pulmonary/*epidemiology
Abstract
BACKGROUND AND OBJECTIVE: The effective control of tuberculosis (TB) requires that people at high risk for the reactivation of TB are identified. Haematological malignancy has been shown to be a risk factor for the development of TB, either through immune suppression by the tumour or through the effects of chemotherapy. This study assessed the hypothesis that solid-organ malignancy is a risk factor for the development of TB. METHODS: A retrospective cohort study was performed to determine the incidence of TB in patients with solid-organ malignancy and in control subjects without malignancy. Risk factors for the development of TB among patients with cancer were also assessed. RESULTS: The study recruited 1809 cases with cancer and 1809 control subjects and followed them for 3 years. The incidence of active TB per 1000 person-years was 3.07 in patients with cancer and 0.77 in controls (P = 0.009). Compared with the control group, patients with cancer had an increased risk of developing TB (incidence rate ratio (IRR) 4.69, 95% CI: 1.52-14.46). Proportional hazards regression analysis showed that the risk factors for development of TB were chronic renal failure (IRR 9.91, 95% CI: 1.17-83.60), old healed TB on CXR (IRR 45.05, 95% CI: 5.74-353.88), and anticancer chemotherapy (IRR 4.32, 95% CI: 1.10-16.89). An interaction between old healed TB and anticancer chemotherapy was observed. CONCLUSION: These findings indicate that immune suppression by cancer or by anticancer chemotherapy increases vulnerability to reactivation of TB, especially in cancer patients with old healed TB.
ISSN
1440-1843 (Electronic)
Language
English
URI
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=18399865

https://hdl.handle.net/10371/68255
DOI
https://doi.org/10.1111/j.1440-1843.2008.01282.x
Files in This Item:
There are no files associated with this item.
Appears in Collections:
College of Medicine/School of Medicine (의과대학/대학원)Internal Medicine (내과학전공)Journal Papers (저널논문_내과학전공)
  • mendeley

Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse